In the last 15 years transcatheter aortic valve implantation (TAVI) has gone from concept to clinical reality, with over 100,000 valves now implanted worldwide {1}. This is one of a number of reports (see also {2,3}) that have emerged regarding small cohorts of patients with infective endocarditis (IE) following TAVI. This recently published multi-centre registry identified a cohort of 53 patients with IE post-TAVI, representing a frequency of 0.5% at 1 year. The mean time to IE from TAVI procedure was 6 months. Interestingly, use of the self-expanding CoreValve system was independently associated with increased risk of IE (HR 3.12, 95% 1.37-7.14, p = 0.007). In-hospital mortality for this group was 47%, reflecting the high rates of staphylococcal infection and frailty of the study population. Further studies are required to better define the incidence, risk factors and clinical outcomes of IE following TAVI. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Bernard D. Prendergast and Thomas J. Cahill.